Physician Photo

Jeffrey Adam Engelman, MD, PhD

  • Phone: 617-724-4000
Departments
Hematology/Oncology
Department of Medicine

Specialties

  • Cancer Center
  • Thoracic Cancers
  • Lung Cancer
Clinical Interests
Lung cancer
Targeted therapies for the treatment of lung cancer
Locations
Boston: Massachusetts General Hospital
Medical Education
MD, PhD, Albert Einstein College of Medicine
Residency, Brigham and Women's Hospital
Fellowship, Dana Farber Cancer Institute
Board Certifications
Medical Oncology, American Board of Internal Medicine
Gender
Male
Patient Age Group
Adult
Accepting New Patients
Accepting New Patients

Cancer Center physicians honored

The Henri and Belinda Termeer Center for Targeted Therapies in the MGH Cancer Center has three new endowed leadership positions.

New SU2C-American Cancer Society Lung Cancer Dream Team Announced

Jeffrey A. Engelman, MD, PhD, associate professor of medicine at Harvard Medical School and director of thoracic oncology at Massachusetts General Hospital Cancer Center, will be leader of a $20 million Dream Team to attack the number one cancer killer in America, lung cancer.

MGH Cancer Center receives second Stand Up to Cancer Dream Team award

Stand Up to Cancer (SU2C) and the American Cancer Society (ACS) announced the formation of a new Dream Team to tackle the problem of lung cancer during the annual meeting of the American Association of Cancer Research (AACR) held April 20 in Philadelphia.

Combination therapy may benefit patients with specific genetic subtype of non-small cell lung cancer

Even when their tumors are shrinking in response to therapy, some non-small cell lung cancer patients have a scattering of cancer cells that are undeterred by the drug, causing the tumor to resume its growth.

New drug successfully treats crizotinib-resistant, ALK-positive lung cancer

A new drug called ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer, both in tumors that have become resistant to crizotinib and in those never treated with the older drug.

Direct drug screening of patient biopsies could overcome resistance to targeted therapy

A new screening platform using cells grown directly from tumor biopsy samples may lead to truly individualized treatment strategies that would get around the problem of treatment resistance, which limits the effectiveness of current targeted therapy drugs.

Hematology/Oncology
55 Fruit Street
Boston, MA 02114-2696

Phone: 617-724-4000